In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Larimar Therapeutics (LRMR – Research Report), with a price target of $21.00. Jonathan Wolleben’s rating is ...
Maintaining a Hold rating on Larimar Therapeutics due to early-stage development of nomlabofusp for Friedreich's ataxia and uncertainty about its functional benefits. The stock has dropped over 50% ...
BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Larimar Therapeutics ( (LRMR)) has issued ...
Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels ...
As of June 30, 2025, the Company had cash, cash equivalents and marketable securities totaling $138.5 million. Together with net proceeds of approximately $65.1 million from the July 2025 public ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback